{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:05:34Z","timestamp":1758758734684,"version":"3.44.0"},"reference-count":61,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zanubrutinib has been approved for treating patients with different lymphoproliferative disorders and now represents a significant breakthrough in treating relapsed\/refractory and previously untreated patients with chronic lymphocytic leukemia (CLL). Because few systematic studies or comparative randomized clinical trials have been conducted, optimal use of zanubrutinib in approved indications may be challenging. This article presents the results of a group discussion among an ad hoc constituted panel of experts to identify and address unmet clinical needs (UCNs) in using zanubrutinib in patients with CLL. Key UCNs were selected according to the criterion of clinical relevance using the Delphi process. Panel members reviewed the results of first\u2010line and upstream controlled trials in which the efficacy and toxicity profile of zanubrutinib and other BTK inhibitors were investigated in patients with CLL. Based on a critical discussion of data, the panel produced recommendations for using zanubrutinib and proposals for new studies to increase the evidence for the optimal treatment of patients with CLL. The recommendations given by the panel are intended for use not only by expert centers but, above all, by less experienced hematologists as well as general practitioners.<\/jats:p>","DOI":"10.1002\/hon.3255","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T05:59:11Z","timestamp":1708063151000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying and addressing unmet clinical needs on the use of\u00a0zanubrutinib in chronic lymphocytic leukemia: A consensus\u2010based position paper from an ad hoc expert panel"],"prefix":"10.1002","volume":"42","author":[{"given":"Francesca Romana","family":"Mauro","sequence":"first","affiliation":[{"name":"Hematology Department of Translational and Precision Medicine \u2018Sapienza\u2019 University  Roma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-2771","authenticated-orcid":false,"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Department of Hematology Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda  Milano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7304-1629","authenticated-orcid":false,"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[{"name":"Division of Hematology Fondazione IRCCS Policlinico San Matteo  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-9474","authenticated-orcid":false,"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[{"name":"Dipartimento Clinico di Scienze Mediche Chirurgiche e della Salute Universit\u00e0 degli Studi di Trieste  Trieste Italy"},{"name":"Unit\u00e0 Complessa Operativa (UCO) Ematologia Azienda Sanitaria Universitaria Giuliano Isontina  Trieste Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis IRCCS Policlinico S. Matteo Foundation  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u2018Ser\u00e0gnoli'  Bologna Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche Universit\u00e0 di Bologna  Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001620\u20102"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_9_4_1","unstructured":"The SEER database the surveillance E and end results (SEER) program of the national cancer institute. Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL).https:\/\/seer.cancer.gov\/statfacts\/html\/clyl; access2022."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201009\u2010806398"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1498844"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010845"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102022\u20100112"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201001\u2010328484"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201003\u2010275305"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(14)71182\u20109"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215637"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1815281"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1713976"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"e_1_2_9_19_1","unstructured":"UsFDA. Available at. Accessed May 2023.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs"},{"key":"e_1_2_9_20_1","unstructured":"EMA.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPARAccessed May 2023."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(22)00293\u20105"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2211582"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509388"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30788\u20105"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812836"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1817073"},{"issue":"5","key":"e_1_2_9_28_1","first-page":"435","article-title":"Ibrutnib and rituximab versus fludarabine cyclophosphamide and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR) interim analysis of a multicentre open\u2010label randomized phase 3 trial","volume":"24","author":"Hilmen P","year":"2023","journal-title":"Lancet Oncol"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010153146"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000845548.49291.01"},{"key":"e_1_2_9_34_1","first-page":"639","article-title":"Zanubruitnib (zanu) vs bendamustine + rituximab (BR) in patients with treatment naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): extended follow.up of the Sequoia study","author":"Munir T","year":"2023","journal-title":"HemaSphere"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2005943"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)30262\u20102"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201019\u20102856"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201008\u2010870238"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03355"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000801"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01210"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17994"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00510"},{"key":"e_1_2_9_48_1","unstructured":"EichhorstB LamannaN O'BrienSMet\u00a0al.Zanubrutinib vs ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/RCLL\/SLL): impact on health\u2010related quality of life (HRQoL). Presented at: European Hematology Association; June 8\u201011 2023."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1400029"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015132"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008325"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00224\u20105"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2300696"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2114110"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_116"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00320\u20109"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14707.33336408"},{"key":"e_1_2_9_59_1","unstructured":"https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010zanubrutinib\u2010chronic\u2010lymphocytic\u2010leukemia\u2010or\u2010small\u2010lymphocytic\u2010lymphoma"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(21)00307\u20100"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_153"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000902\u2010x"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:36:00Z","timestamp":1758688560000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/hon.3255"],"URL":"https:\/\/doi.org\/10.1002\/hon.3255","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"type":"print","value":"0278-0232"},{"type":"electronic","value":"1099-1069"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"2023-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3255"}}